ARQT at a glance
Arcutis Biotherapeutics, Inc. (ARQT, SEC CIK 1787306) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and Form 4 insider filings as recently as September 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Arcutis Biotherapeutics, Inc. (ARQT) reported revenue of $376.1 million (up 91.3% from FY2024) and a net loss of $16.1 million. Diluted EPS was -$0.13.
- As of June 30, 2026, 31 institutional investment managers tracked by SignalX reported holding Arcutis Biotherapeutics, Inc. (ARQT) shares worth $1.2 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Matsuda Masaru on September 16, 2026 of 3,674 shares at $25.00 per share.
- In the last 90 days, ARQT insiders reported 0 open-market purchases ($0) and 14 open-market sales ($2.3M) on Form 4, a net sale of $2.3M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $376.1M
- +91.3% vs prior year
- Insiders · 90 days
- 0 buys · 14 sells
- Net −$2.3M
- 13F holders
- 31 funds
- $1.2B · +2 vs prior quarter
- Latest 8-K
- Aug 5, 2026
- Item 2.02 · Item 5.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Commercial-stage biopharma specializing in differentiated topical and systemic dermatology treatments targeting immune-mediated diseases
- New approvals: ZORYVE foam 0.3% for seborrheic dermatitis (FDA Dec 2023), scalp/body plaque psoriasis (FDA May 2025); ZORYVE cream 0.15% for atopic dermatitis (FDA July 2024); ZORYVE cream 0.05% for ages 2-5 (FDA Oct 2025)
- Strategic shift: Terminated primary care promotion agreement with Kowa (Jan 2026), refocusing commercial efforts internally; expanded global licensing in Greater China, Southeast Asia, Japan
- Quantitative highlight: Over 8 approvals/commercial launches of ZORYVE formulations across multiple indications from 2023 to 2026; Phase 1 study for acquired ARQ-234 expected Q1 2026
- Noteworthy fact: Submitted sNDA for ZORYVE cream 0.3% pediatric use down to age 2 with PDUFA June 29, 2026; positive phase 2 topline data for ZORYVE cream 0.05% in infants 3 months–2 years
Risk Factors
- Regulatory risk: oversight of cybersecurity mandated by SEC guidance on disclosure controls and procedures
- Operational vulnerability: reliance on VP CT&S with 20 years IT experience for day-to-day cybersecurity risk management
- Financial risk: potential material impact from cybersecurity incidents reported quarterly to Audit Committee
- Competitive risk: exposure to evolving cyber threats requiring continuous updates to cybersecurity tools and strategies
Management Discussion & Analysis
- Revenue $372.1M in 2025, up 123% YoY from $166.5M in 2024; ZORYVE foam up $110.4M, cream 0.15% up $58.4M, cream 0.3% up $35.9M
- Operating expenses increased; R&D $77.1M in 2025 vs $76.4M 2024 (+1%), SG&A up by $45.2M driven by sales/marketing and compensation
- Best segment: ZORYVE foam $181.9M in 2025 vs $71.5M 2024 (+154%); worst segment: ZORYVE cream 0.3% with smaller 42% growth
- Cash, cash equivalents, and marketable securities at $221.3M end 2025 vs $228.6M in 2024; paid down $100M debt principal in Oct 2024
- Management expects increased R&D and SG&A in 2026 driven by ARQ-234 clinical development and continued ZORYVE commercialization; potential funding needs from equity/debt if cash insufficient
AI summary of the ARQT 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Product revenue $129.9M, up 59% YoY from $81.5M
- Best performer: ZORYVE foam $67.4M, up 72% YoY
- ZORYVE cream 0.05% revenue $2.9M, launched October 2025
- Research and development expense $20.4M, up 5% YoY; SG&A up 19%
- Cash, restricted cash, and marketable securities $238.9M; $100.0M debt outstanding; sufficient for at least 12 months
Risk Factors
- No risk-factors section provided; supplied text begins with Item 2 and contains no comparison with the 10-K
- CEO trading-plan change: terminated June 4, 2026 plan covering up to 325,000 shares
- CEO replacement plan: potential exercise and sale of up to 325,000 options through August 31, 2027
- Chief Legal Officer plan: potential exercise and sale of up to 40,000 options plus 45,792 shares through September 1, 2027
AI summary of the ARQT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release issued August 5, 2026 and furnished as Exhibit 99.1
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Chief Commercial Officer L. Todd Edwards departing August 21, 2026 for external opportunity, without reported disagreement
- Robert Lisicki appointed interim executive vice president August 17 and interim chief commercial officer August 21
Item EX-99.1: Item EX-99.1
- Q2 product revenue $129.9M, up 59% YoY and 23% sequentially, confirming accelerating ZORYVE demand
- 2026 sales guidance raised to $525M–$540M from $480M–$495M, signaling stronger commercial momentum
Item 7.01: Regulation FD Disclosure
- Press release announces Mr. Peetz’s appointment, signaling a leadership change at Arcutis
- Exhibit 99.1 contains the substantive appointment details and any related transition information
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Board expanded from nine to ten directors with Christopher Peetz appointed independent Class III director through the 2029 annual meeting
- Mirum Pharmaceuticals CEO brings commercial-stage biotechnology and prior M&A experience to Arcutis’s board
Item EX-99.1: Item EX-99.1
- Christopher Peetz appointed Arcutis director effective July 15, 2026
- Mirum Pharmaceuticals CEO brings commercialization, pipeline-building, and acquisition expertise
Item 5.07: Submission of Matters to a Vote of Security Holders
- Stockholders approved all three proposals at the June 5, 2026 annual meeting
- Three Class III directors elected through 2029; Watanabe and Krishnamohan received strongest support
Item 8.01: Other Events
- Revised non-employee director compensation program effective at the Annual Meeting
- Annual cash and equity compensation terms updated for eligible directors
AI summaries of ARQT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ARQT
Don't miss the next ARQT filing
- Alerts as it files. A push when ARQT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ARQT, by share count.
- Ask anything. An AI agent that reads every ARQT filing and answers with sources.
ARQT alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Matsuda Masaru | Sell | Sep 16, 2026 | 3,674 | $25.00 |
| Welgus Howard G. | M | Sep 15, 2026 | 1,019 | - |
| Welgus Howard G. | M | Sep 15, 2026 | 822 | - |
| Welgus Howard G. | Sell | Sep 15, 2026 | 4,730 | $24.18 |
| Welgus Howard G. | M | Sep 15, 2026 | 822 | $6.52 |
| Welgus Howard G. | M | Sep 15, 2026 | 2,255 | - |
| Welgus Howard G. | M | Sep 15, 2026 | 2,255 | $8.63 |
| Welgus Howard G. | M | Sep 15, 2026 | 1,019 | $7.51 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $59.6M | $196.5M | $376.1M |
| Operating Income | - | -$128.4M | -$12.2M |
| Net Income | -$262.1M | -$140.0M | -$16.1M |
| Op. Margin | - | -65.3% | -3.3% |
| Net Margin | -439.8% | -71.3% | -4.3% |
| Balance Sheet | |||
| Total Assets | - | $348.9M | $433.0M |
| Equity | $88.7M | $157.5M | $189.5M |
| ROE | -295.6% | -88.9% | -8.5% |
| Per Share | |||
| EPS | $-3.78 | $-1.16 | $-0.13 |
| Cash Flow | |||
| Operating CF | - | -$112.2M | -$5.6M |
| CapEx | - | $143K | $686K |
Source: XBRL data in Arcutis Biotherapeutics, Inc. (ARQT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ARQT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 31 | $1.17B |
| Q1 2026 | 29 | $932.1M |
| Q4 2025 | 25 | $1.09B |
| Q3 2025 | 24 | $658.9M |
| Q2 2025 | 25 | $525.4M |
| Q1 2025 | 24 | $424.5M |
| Q4 2024 | 20 | $327.2M |
| Q3 2024 | 16 | $183.0M |
- D.E. Shaw & Co+1.45M (+58%)
- BlackRock+1.35M (+15%)
- Citadel Advisors LLC+1.14M (+7333%)
- Bank of America Corp+766.1K (+34%)
- Millennium Management+514.7K (+1043%)
- State Street Corp−473.4K (-8%)
- Renaissance Technologies LLC−382.6K (-87%)
- Franklin Resources−367.0K (-16%)
- T. Rowe Price Group−290.4K (-65%)
- Prudential Financial−230.6K (-90%)
- Citizens Financial Group+35.1K
- Allstate+9.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 194 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ARQT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 24, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| SC 13G | Aug 14, 2026 | - | - | |
| 4 | Aug 13, 2026 | - | - | - |
| SC 13G | Aug 7, 2026 | - | - | |
| 4 | Aug 5, 2026 | - | - | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 5, 2026 | - | - | - |
| 4 | Aug 5, 2026 | - | - | - |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 4 | Jul 17, 2026 | - | - | - |
| 4 | Jul 17, 2026 | - | - | - |
| 8-K | Jul 16, 2026 | - | Analysis | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 8-K | Jun 9, 2026 | - | Analysis | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
ARQT SEC filings: frequently asked questions
Are ARQT insiders buying or selling?
In the last 90 days, Arcutis Biotherapeutics, Inc. (ARQT) officers, directors and 10% owners reported no open-market purchases and 14 open-market sales worth $2.3 million by 5 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ARQT stock?
As of June 30, 2026, the largest Arcutis Biotherapeutics, Inc. (ARQT) holders among the 13F filers tracked by SignalX were BlackRock ($276.5 million), State Street Corp ($152.7 million), Vanguard Capital Management LLC ($130.8 million), Morgan Stanley ($116.7 million), D.E. Shaw & Co ($103.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ARQT's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Arcutis Biotherapeutics, Inc. (ARQT) reported revenue of $376.1 million (up 91.3% from FY2024) and a net loss of $16.1 million. Diluted EPS was -$0.13. The figures come from the XBRL data in the 10-K.
What are the main risks in ARQT's latest 10-K?
In the 10-K filed February 25, 2026, Arcutis Biotherapeutics, Inc. (ARQT) flagged: Regulatory risk: oversight of cybersecurity mandated by SEC guidance on disclosure controls and procedures. Operational vulnerability: reliance on VP CT&S with 20 years IT experience for day-to-day cybersecurity risk management. (AI summary of the Risk Factors section.)
What did ARQT report in its latest 8-K?
Arcutis Biotherapeutics, Inc. (ARQT) filed an 8-K on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 5.02 (Departure/Appointment of Directors or Principal Officers). Q2 2026 financial results for quarter ended June 30, 2026.
What are the latest ARQT SEC filings?
Arcutis Biotherapeutics, Inc. (ARQT) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and a Form 4 insider filing on September 18, 2026.
What is ARQT's SEC CIK number?
Arcutis Biotherapeutics, Inc. (ARQT)'s SEC Central Index Key (CIK) is 1787306. EDGAR lists every ARQT filing under that number.
Ask anything about ARQT
The research agent reads ARQT's filings, financials, insider trades and 13F holders, then answers with sources.